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Amyloid precursor protein (APP), implicated in Alzheimer’s disease, is a transmembrane protein of undetermined function. APP
is cleaved by gamma-secretase that releases the APP intracellular domain (AICD)in the cytoplasm. In vitro and in vivo studies have
implicated the role of AICD in cell signaling and transcriptional regulation of Gsk3β, KAI1, BACE1, EGFR, and other proteins.
In this study, by overexpressing AICD in mouse neuroblastoma cell lines, we have demonstrated the alteration in the expressions
of two proteins, patched homolog 1 (PTCH1), a receptor for sonic hedgehog signaling, and transient receptor potential cation
channel subfamily C member 5 (TRPC5), a component of receptor-activated nonselective calcium permeant cation channel.
Our results indicate the possibility of regulation by AICD in developmental processes as well as in the maintenance of calcium
homeostasis at the transcription level.
1.Introduction
Alzheimer’s disease (AD) is an irreversible, progressive neu-
rodegenerative disorder that occurs gradually and results in
memory loss, unusual behavior, personality changes, and a
decline in thinking abilities. A fundamental abnormality that
playsapivotalroleinthedysfunctionanddeathofneuronsin
AD is altered proteolytic cleavage of APP. The function of the
APP holoprotein is not yet established and mice lacking the
APP gene show relatively minor neurological impairments.
This subtle phenotype is probably due to compensatory
eﬀects mediated by two other members of the APP gene
family: amyloid-precursor-like protein-1 and -2 (APLP1 and
APLP2). This view is supported by evidence showing that
the combined ablation of APP and APLP2, both APLP genes
or all three family members together leads to early postnatal
lethality [1]. Both the amyloidogenic and nonamyloidogenic
pathways, that is, the cleavages of APP by β-a n dα-sec-
retases, respectively, liberate the soluble ectodomain of APP
(ectodomain shedding) and retain the C-terminal fragments
(CTF) (CT99 and CT83, resp.). Subsequent cleavages by
γ-secretase in the transmembrane domain generate the
amyloidogenic Aβ peptide or the nonamyloidogenic p3
peptide along with the intracellular C-terminal domain of
APP (AICD). Biochemical and genetic interaction screens
have led to the identiﬁcation of both extracellular and mul-
tiple intracellular binding partners, which seem to anchor
the APP/APLP C-termini to a complex protein network
at the cell surface, which may transduce various cellular
responses [2, 3]. Notably, a highly conserved cytoplasmic—
682YENPTY687—motif is present in all APP/APLP family
members, which confers clathrin-mediated endocytosis and
was shown to bind several multidomain adaptor proteins,
including X11/Mints, Fe65 family proteins and mDab [4].
A number of type-I transmembrane proteins including
Notch, p75NTR, CD44, ErbB4, neuregulin-1, and alcadein
undergo a similar secretase mediated processing leading
to ectodomain shedding and generation of intracellular
domains (ICD’s) [5]. Some of these ICD’s are known to take
part in cellular diﬀerentiation and development by nuclear
signaling and transcriptional transactivation [6]. Like NICD
(Notch intracellular domain), several recent studies have
suggestedthatAICDhastransactivationactivityandcanreg-
ulatetranscription ofmultiple genesincluding APP,GSK-3β,2 International Journal of Alzheimer’s Disease
Table 1: Primer sequences and PCR conditions of real-time PCR.
Name of the genes PCR condition PCR Cycle Primer sequences (5 -3 ) Size (bp)
PTCHI
95◦C→10min
35 GAAAAATGAGCAGAACCATGG
TGTCTTCCTTCTGAACCCCTG
102 [95◦C3 0s e c ,5 0 ◦C
30sec, 60◦C 1min]
72◦C→10min
TRPC5
95◦C→10min
35 TTCCAGCTCTCTTCACTGTGC
AAGTCACAAGCCTCTCCCCAA
102 [95◦C3 0s e c ,5 0 ◦C
30sec, 60◦C 1min]
72◦C→10min
Beta actin
95◦C→10min
35 TCCTGTGGCATCCACGAAACT
GAAGCATTTGCGGTGGACGAT
315 [95◦C3 0s e c ,5 5 ◦C
30sec, 60◦C 1min]
72◦C→10min
KAI1, neprilysin, BACE, and EGFR [7–11]. Recently, it has
been shown that AICD-mediated transcriptional regulation
of EGFR by directly binding to the EGFR promoter [11].
The role of APP in neuronal development and in calcium
homeostasis is well established [1, 12, 13]. The expression
of APP in brain is developmentally regulated and it is
expressed ubiquitously in diﬀerentiated neurons. APP is
axonally transported and secreted forms of APP (sAPPs)
are released from neurons in an activity-driven manner.
Secreted APPs modulate neuronal excitability, counteract
eﬀects of glutamate on growth cone behaviors, and increase
synaptic complexity [14]. Moreover, aberrant processing
of APP can also cause neurodegeneration by impairing a
neuroprotective function sAPPs which normally regulate
calcium homeostasis [12, 15].
But the role of AICD, if any, in both developmental
processes and in maintenance of calcium ion homeostasis
is yet to be elucidated. In the present study, we intended
to look into the possibility of AICD having any role in
the transcriptional regulation of the components of sonic
hedgehog pathway and calcium channel forming proteins.
Initially, microarray analysis was done to screen the genes
whose expression would alter upon AICD overexpression
(data not shown).
2.MaterialsandMethods
2.1. Cloning of AICD in pGFP C1 Vector. For the overexp-
ression of AICD in mammalian cell line, it was cloned
in pGFP vector. Speciﬁc primers for AICD (Forward: 5 
ACGCGTCGACAAGAAGAAACAGTACACATCC3  and the
Reverse: 5 CGGGATCCTAGTTCTGCATCTGCTCAAAGAA
C3 ) with adaptors (underlined), for the restriction enzymes
(RE) SalI and BamH1, were synthesized (Integrated DNA
Technologies) to amplify the domain using brain c-DNA
library (Stratagen) as template. PCR products were digested
with SalI and BamH1 (New England Biolabs) and ligated to
pGFP C1 vector (BD Biosciences). Construct was conﬁrmed
both by DNA sequencing and restriction enzyme digestion.
2.2. Cell Culture and Transfection. Neuro 2A cells were
obtained from National Cell Science Centre, Pune, India
a n dw e r ec u l t u r e di nD M E M( H i M e d i a )s u p p l e m e n t e dw i t h
10% fetal bovine serum (Invitrogen) at 37◦Ci n5 %C O 2
atmosphere under humidiﬁed condition. Transfection of
cells with empty vector (pGFP C1) or AICD-GFP was
performed using Lipofectamine 2000 Transfection Reagent
(Invitrogen).
2.3. Protein Extraction. For extraction of proteins, PBS-
washed pellets from cell lines were lysed on ice in lysis buﬀer
(50mM Tris-HCl, pH 7.5, 150mM NaCl, 15mM EDTA,
0.5% Triton X-100) for 30 min in presence of Complete
protease inhibitor (Roche Diagnostics) and centrifuged
at 13,000rpm for 15 minutes. Protein concentration was
determined by Bradford protein estimation assay.
2.4. RNA Isolation, c-DNA Preparation and Real-Time PCR.
RNA was isolated from Neuro 2A cells by RNeasy Mini
Kit (Qiagen, Hilden, Germany) following the manufacturers
protocol. RNA equivalent to 500ng–1μg was taken to
synthesize the ﬁrst strand cDNA using random hexamer
primers and reverse transcriptase (Invitrogen). Real time
RT-PCR reaction was carried out using Syber green 2X
Universal PCR Master Mix (Applied Biosystems, USA) in
ABI Prism 7500 sequence detection system. Each reaction
was performed in triplicate using 100ng of total RNA using
correspondingprimersequences(primersequencesandPCR
conditions were mentioned in the Table 1). For each gene,
nontemplate control was used at the same condition to
ascertain the baseline and threshold value for the analysis.
The absolute quantiﬁcation given by the software was in
termsofCtvalues.Therelativequantiﬁcationofatargetgene
in a sample compared to parental cell is expressed in terms
of 2−ΔΔCt values after normalization with respect to internal
control (β-actin gene).
2.5. Western Blot. Proteins were separated on SDS-
polyacrylamide gels and transferred onto PVDF membranesInternational Journal of Alzheimer’s Disease 3
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Figure 1: (a) RNA was isolated from Neuro 2A cells transfected with either GFP or AICD-GFP. The ﬁrst strand cDNA was synthesized using
random hexamer primers and reverse transcriptase. Using that c-DNA as template, expression of PTCH1 and TRPC5 were also checked
by real-time PCR in both the cell lines. The relative quantiﬁcation of both the genes in AICD-GFP transfected cell compared to only GFP
transfected cell were expressed in terms of 2−ΔΔCt values after normalization with respect to internal control (beta-actin gene) and plotted
in log scale (log10(Fold change)) ∗ indicated P<. 02 and ∗∗ indicated P<. 05. (b) Proteins were prepared from both GFP and AICD-GFP
transfected cells after 24 hours of transfection, run on SDS-PAGE and western blot was done with antibody against PTCH1 (i) as well as
TRPC5 (iii) and beta actin as loading control in both the cases. Fold change was calculated by densitometry analysis taking beta-actin as
loading control (ii) and (iv). ∗∗∗ indicated P<. 05 and ∗∗∗∗ indicated P<. 005.4 International Journal of Alzheimer’s Disease
(Millipore Corporation), which were blocked by incubation
in 5% dried milk in TBST (50mM Tris-HCl, 150mM NaCl,
pH 7.5 containing 0.05% Tween 20). Membranes were
probed with primary antibodies against PTCH (ab53715,
Abcamplc,1:1000);TRPC5(ab58374,Abcamplc,1μg/mL);
beta actin (loading control for whole cell extracts; Abcam
plc, 1:5000). HRP-conjugated antibodies (Chemicon;
1:5000) were then added to the blots. Immunoreactive
bands were detected with enhanced chemiluminescence
reagent (Super Signal West Pico Substrate; Pierce) and
signals were visualized by exposing the membranes to
ECL Hyperﬁlm (Amersham Biosciences). Quantiﬁcation of
westernblotswascarriedoutusingQuantityOnesoftwareof
Bio-Rad. At least three separate experiments were analyzed
and band intensities were normalized to loading control.
P-values were determined using unpaired t-tests.
Mean and standard deviation were calculated by Micro-
soft Oﬃce Excel 2007. The error bar represents standard
error ((standard deviation/
√
n) n = sample size).
3. Results andDiscussion
From microarray experiment we got the hint that AICD
overexpression might alter the expression level of PTCH1
and TRPC5 (data not shown). To provide further evidence,
the mRNA expression levels of both the proteins were
checked by real-time PCR using total RNA from AICD-
GFP overexpressed cells and compared those with the
expression of only pGFP C1 transfected cells. About 2-
fold increase and 3-fold decrease in the expressions of
PTCH1 and TRPC5, respectively, was observed upon AICD
overexpression (Figure 1(a)). The changes in the expressions
ofthe genesat RNA levelwasfurtherveriﬁed at protein levels
also. By westernblot analysis it was revealed thatendogenous
PTCH1 level was raised 1.5 fold (Figure 1(b), panels (i) and
(ii)) and TRPC5 level was decreased 9 fold (Figure 1(b),
panels (iii) and (iv)) in AICD-GFP overexpressing Neuro 2A
cells compared to control.
PTCH1 acts as a receptor for sonic hedgehog (SHH)
[16] and seem to have a tumor suppressor function, as
inactivation of this protein is probably a necessary, if not
suﬃcient step for tumorigenesis [17]. Defects in PTCH1
are known to be a cause of sporadic basal cell carcinoma
(BCC) [18]. Hence overexpression of PTCH1 by AICD could
be a protective measure of cells against tumorigenesis. This
observation seems to be interesting because AICD is previ-
ously reported to modulate EGFR-mediated tumorigenesis
by reducing the expression of EGFR [11].
On the other hand TRPC5 forms a receptor-activated
nonselective calcium permeant cation channel. TRPC1 and
TRPC5 are subunits of a heteromeric neuronal channel in
mammalian brain [19] .T R P C 5i sr e p o r t e dt oc o l o c a l i z e
with stathmin-like-2, a neuronal growth protein, within
the vesicles and in the growth cone. A dominant-negative
form of TRPC5 allowed signiﬁcantly longer neurites and
ﬁlopodia to form, suggesting that TRPC5 regulates neuronal
growth [20]. It was also reported that inﬂuxes of calcium via
voltage-gatedchannelsplayaroleinneuronaloutgrowthand
suggested that TRPC5 is a candidate for the regulation of
calcium waves [20]. A decrease in the expression of TRPC5
by AICD overexpression might aﬀect neurite outgrowth.
4. Conclusion
In conclusion, our results suggest that overexpression of
AICD can modulate both developmental and degenerative
pathways in the cell. Whether the cell would take the survival
or the degenerative route at the end depends on other
regulatory parameters.
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